Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.75 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 4/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193323 | 0.91 | DRD2 (0.76) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL1193550 | 0.90 | HTR1A (0.77) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL10415968 | 0.88 | HTR1A (0.75) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL6526368 | 0.87 | DRD2 (0.85) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL3261221 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL8363314 | 0.86 | DRD2 (0.77) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL31060769 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL9293656 | 0.85 | DRD2 (0.66) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL1253155 | 0.84 | DRD2 (0.75) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL4404160 | 0.84 | DRD2 (0.75) | DRD2DRD3HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| WO-2014079504-A1 | POLYCYCLIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF | BIOFORDRUG S.R.L. (IT) | 2014-05-30 | — | — | WO | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-5922874-A | Process for preparing N-aryl-N'-alkyl-piperazines | BAYER ATKIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0895993-A1 | Process for the preparation of N-aryl-N'aklyl-piperazines | BAYER AG (DE) | 1999-02-10 | — | — | EP | disclosed |
| US-5712270-A | TREATING PARKINSON*S DISEASE, DOWN*S SYNDROME, AND ALZHEIMER*S DISEASE WITH COGNITION ACTIVATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | disclosed |
| EP-0548798-A1 | Antiviral agent | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0094159-B1 | DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-14 | — | — | EP | disclosed |
| US-4892875-A | HYPOTENSIVE, RENAL VASODILATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| US-4873331-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-10-10 | — | — | US | disclosed |
| US-4868181-A | CALCIUM CHANNEL BLOCKERS, ADRENERGIC BLOCKING AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4797489-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORP. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0255710-A2 | 1,4-Dihydropyridine derivatives with calcium agonist and alpha-1-antagonist activity | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-02-10 | — | — | EP | disclosed |
| EP-0205511-A1 | NEW PIPERAZINE DERIVATIVES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| WO-1986003748-A1 | NEW PIPERAZINE DERIVATIVES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT M (DE) | 1986-07-03 | — | — | WO | disclosed |
| EP-0094159-A1 | Dihydropyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | DRD2 16/4885DRD3 41/4885HTR1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.